Author:
Kim Jeong Eun,Ryoo Baek-Yeol,Ryu Min-Hee,Chang Heung-Moon,Suh Dong Jin,Lee Han Chu,Lim Young-Suk,Kim Kang Mo,Kang Yoon-Koo
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference7 articles.
1. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42:1208–1236
2. Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34
3. Duffaud F, Therasse P (2000) New guidelines to evaluate the response to treatment in solid tumors. Bull Cancer 87:881–886
4. Lee S, Kang Y, Chang H, Lee J, Kim T, Kim J, Kim K, Lee H, Lee Y, Suh D (2009) Sorafenib in patients with advanced hepatocellular carcinoma: experience in a single institute. 2009 gastrointestinal cancers symposium 256
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390
Cited by
72 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献